SCHEMBL4536701

SCHEMBL4536701

Cc1ccccc1OC(C(=O)NO)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.48
HDAC7 Q8WUI4 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
LMNA P02545 2/20 0.46
CYP1A2 P05177 4/20 0.46
CYP3A4 P08684 4/20 0.46
CYP2D6 P10635 3/20 0.46
SLC6A2 P23975 3/20 0.46
TSHR P16473 3/20 0.46
CHRM1 P11229 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4533785 0.84 KMT2A (0.53) MMP8HDAC7HDAC3HDAC4HDAC1
SCHEMBL4534368 0.84 ALDH1A1 (0.50) MMP8HDAC7HDAC3HDAC4HDAC1
SCHEMBL29163286 0.83 KMT2A (0.51) SMN1; SMN2LMNACYP1A2CYP3A4CYP2D6
SCHEMBL4534205 0.82 HDAC7 (0.45) MMP8HDAC7HDAC3HDAC4HDAC1
SCHEMBL4540199 0.81 ALDH1A1 (0.50) MMP8HDAC7HDAC3HDAC4HDAC1
SCHEMBL4526444 0.81 KMT2A (0.51) MMP8HDAC7HDAC3HDAC4HDAC1
SCHEMBL30285514 0.81 SMN1; SMN2 (0.48) SMN1; SMN2LMNACYP1A2CYP3A4CYP2D6
SCHEMBL4535628 0.81 KDM4E (0.44) MMP8HDAC7HDAC3HDAC4HDAC1
SCHEMBL4561616 0.80 HDAC7 (0.46) MMP8HDAC7HDAC3HDAC4HDAC1
SCHEMBL28887350 0.79 SMN1; SMN2 (0.64) SMN1; SMN2LMNACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 MMP8 648/4885HDAC7 7/4885HDAC3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.